相关实验视频

Updated: Jul 8, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

ALKemy用于增强神经母细胞瘤的奇米尔抗原受体T细胞免疫治疗

¹Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

|December 12, 2023

概括

无细胞淋巴瘤激酶 (ALK) 抑制剂提高了ALK特异性CAR T细胞治疗神经母细胞瘤的有效性. 这种方法增加了癌细胞的点密度,改善了固体瘤中CAR T细胞的功能.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
癌症生物学癌症生物学

背景情况:

化学抗原受体 (CAR) T细胞免疫疗法显示出希望,但由于缺乏合适的点,在固体瘤中面临挑战.
识别和向癌细胞上的特定抗原对于有效的CAR T细胞治疗至关重要.

研究的目的:

调查形淋巴瘤激酶 (ALK) 抑制剂是否可以提高ALK特异性CAR T细胞治疗神经母细胞瘤的疗效.
确定ALK抑制剂可能增强固体瘤中CAR T细胞功能的机制.

主要方法:

在神经母细胞瘤的临床前模型中使用ALK抑制剂与ALK特异性CAR T细胞结合使用.
评估CAR T细胞功能,包括增殖,细胞因子生产和瘤细胞杀死.
量化了对神经母细胞瘤细胞的形淋巴瘤激酶 (ALK) 表达和点密度.

主要成果:

无细胞淋巴瘤激酶 (ALK) 抑制剂显著增强了ALK特异性CAR T细胞的抗瘤活性.
用ALK抑制剂治疗导致ALK在神经母细胞细胞上的表达增加,从而增加了点密度.
提高目标密度导致CAR T细胞持续性和效应器功能得到改善.

结论:

无细胞淋巴瘤激酶 (ALK) 抑制剂是克服CAR T细胞治疗神经母细胞瘤的目标限制的可行策略.
这种方法有可能改善其他具有可向抗原的固体癌症中CAR-T细胞免疫治疗结果.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.